PolyPid

PolyPid announced two transformative milestones: the FDA's acceptance for filing of its new drug application, or NDA, for D-PLEX100 with Priority Review, and the signing of an exclusive commercialization partnership with Azurity Pharmaceuticals for the United States and Canada. The FDA granted Priority Review with a PDUFA goal date of November 28, 2026, and identified no filing review issues. Under the Azurity agreement, PolyPid has secured $30 million in upfront and near-term milestone payments and is eligible for over $290 million in additional regulatory, launch, and sales milestones, plus tiered royalties ranging from mid-teens to mid-20s percentages and a transfer price on every unit supplied. PolyPid expects to submit a Marketing Authorization Application to the European Medicines Agency in the third quarter of 2026 and anticipates a commercial launch of D-PLEX100 by Azurity in early 2027. The company reported a net loss of $7.8 million for the second quarter of 2026, with cash and cash equivalents of $6.6 million as of June 30, 2026, and expects existing cash resources to fund operations into 2028.

The U.S. Food and Drug Administration has accepted PolyPid's New Drug Application for D-PLEX100 with Priority Review, setting a target action date of November 28, 2026. The FDA identified no filing review issues, and the Priority Review shortens the review timeline to approximately six months, moving the decision about one quarter ahead of the company's previous first-quarter 2027 guidance. The acceptance triggers a $15 million milestone payment from Azurity Pharmaceuticals, completing $30 million in upfront and near-term milestone payments under the exclusive U.S. and Canada commercialization partnership announced on July 17, 2026. D-PLEX100 is being developed for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, and if approved, a potential U.S. commercial launch by Azurity is expected in early 2027.

PolyPid has entered an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100 in the United States and Canada. PolyPid will receive a $15 million upfront payment and a $15 million near-term milestone payment upon FDA acceptance of the NDA, expected in August 2026, with up to approximately $300 million in additional regulatory, development, and sales-based milestones, plus tiered royalties from mid-teen to mid-twenties percentages. Azurity will commercialize D-PLEX100 upon approval, leveraging its first-in-class commercial model, while PolyPid will manufacture and supply the product. Azurity will also fund clinical development for potential label expansion beyond abdominal surgical site infections. The partnership follows positive Phase 3 SHIELD II results showing a 60% relative risk reduction in SSI incidence, and a U.S. launch is targeted for the first quarter of 2027.